Does CHIP Cover GLP-1 for Teens?

Published by The RX Index · Last verified September 24, 2026 · How we checked this page

Disclosure: The RX Index earns money from some adult telehealth links elsewhere on the site. This page does not link a minor to an adult telehealth or compounded-medication program.

Sometimes. CHIP can cover a GLP-1 for a teen, but there is no single national rule. The first question is whether the teen has Medicaid-expansion CHIP or separate CHIP. Medicaid-expansion CHIP includes EPSDT. Separate CHIP follows its state-designed benefit, and some states elected the full EPSDT benefit. Approval still depends on the exact medicine, diagnosis, plan, and prior authorization.

So does CHIP cover GLP-1 for teens where you live? Here is the part that should help you breathe a little easier. We matched all 50 states and the District of Columbia to KFF’s children-specific EPSDT status table for policies in place as of January 2026, then checked the legal framework against current CMS sources. Your state is in the table below. So are the one phone call, the doctor’s checklist, and the appeal steps that can move a request forward.

The 20-second version

• Two GLP-1 medicines have an FDA-approved teen weight-management use.
• The standard Wegovy injection pathway, for ages 12 and up with obesity. Pediatric maintenance dosing is 1.7 mg or 2.4 mg weekly; the 7.2 mg injection is adult-only.
• Saxenda, for pediatric patients age 12 and up who have obesity and weigh more than 60 kg (132 lb).
• Some GLP-1 or incretin medicines have a different teen use. Mounjaro, Victoza, and Trulicity have a type 2 diabetes use starting at age 10. That is a separate coverage lane.
• Zepbound, Ozempic, Foundayo, Wegovy tablets, and the Wegovy 7.2 mg injection do not have a pediatric indication.
• EPSDT depends on the CHIP path. It applies to Medicaid-expansion CHIP. A separate CHIP program gets EPSDT only if the state elected it for that group.
• Prior authorization is common. That is the plan’s review before it agrees to pay.
• A “yes” in the state table is not an approval. It tells you which benefit rules should be applied to the request.
• A managed-care appeal often starts with a 60-day deadline. The date and instructions on the written notice control your case.

This page is for you if you are a parent or guardian of a teen on CHIP or Medicaid and a clinician has brought up Wegovy, Saxenda, or a GLP-1 for type 2 diabetes. It is also for you if the pharmacy or plan just said “no.”

This page is not for you if:

• You are an adult checking your own coverage. Go to Medicaid GLP-1 coverage by state.
• Your teen has job-based or private insurance. Go to Wegovy for teens insurance coverage.
• Your child is under 12 and the question is weight management. No GLP-1 has an FDA-approved weight-management use before age 12. Type 2 diabetes is a different question because several medicines have a diabetes indication starting at age 10.
• You need help choosing a medicine. That is a medical decision for your teen’s clinician. This page is about coverage and paperwork.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. For a teen, that job is simple: find the covered pediatric path. There is no provider pitch for your teen here.

Find your teen’s situation in 10 seconds

The one thing we will not sugarcoat: separate CHIP may not include EPSDT. Even when EPSDT applies, it does not guarantee Wegovy, Saxenda, or any other brand. It means the plan must apply the child’s benefit and medical-necessity rules to the individual request instead of treating an adult policy as the whole answer.

If your family’s income has dropped, it is worth asking whether your teen now qualifies for Medicaid. Do not cancel current coverage while you check.

Separate CHIP also has appeal protections. In managed care, a formal adverse benefit decision should come with a written reason, a plan appeal, and a state external review after the plan upholds the decision. Some “no” answers are only missing paperwork, and those are fixable. Jump to the denial fixes.

Your 3-step plan:

1. Grab your teen’s insurance card. Ten seconds.
2. Make one call using the script below. You will learn which kind of CHIP your teen has and which drug policy controls.
3. Bring the checklist to the doctor. It lists what a strong prior-authorization request needs.

It depends on your situation. The right GLP-1 treatment path is not the same for every teen. It depends on:

• your state
• whether your teen’s CHIP runs through Medicaid or is separate
• the plan’s formulary, which is its covered-drug list
• your teen’s age and diagnosis
• the exact medicine and formulation
• whether EPSDT applies

Because a general answer cannot resolve those details, use The RX Index’s Find My GLP-1 Path tool. The under-18 branch gives you a pediatric coverage checklist, not an adult provider match. Get my teen’s CHIP action plan → Answer four quick questions. See which rule applies, plus the call script and doctor checklist for your state. It is free, takes about 60 seconds, and does not ask for a name, date of birth, member ID, or health records.

✔ What we actually verified on September 24, 2026

• The federal CHIP and EPSDT framework from CMS and the federal regulations, including the difference between Medicaid-expansion CHIP and separate CHIP.
• KFF’s state-by-state EPSDT status for children’s CHIP in all 50 states and the District of Columbia, reflecting policies in place as of January 2026.
• Current pediatric label status for Wegovy, Saxenda, Mounjaro, Victoza, Trulicity, Zepbound, Ozempic, and Foundayo.
• Texas Medicaid’s standard Wegovy checklist dated May 8, 2026.
• Federal managed-care appeal timelines.
• Novo Nordisk’s current listed Wegovy self-pay prices.

What we cannot verify for you:

• your teen’s exact plan drug list
• your teen’s medical eligibility
• whether a particular request will be approved
• the deadline on a notice we cannot see

Only the current plan documents, the written notice, and your teen’s clinician can answer those.

What each source proves — and what it does not

Which GLP-1 medicines are approved for teens?

Two GLP-1 medicines have an FDA-approved pediatric weight-management use: the standard Wegovy injection pathway for ages 12 and up with obesity, and Saxenda for pediatric patients age 12 and up who have obesity and weigh more than 60 kg (132 lb). For Wegovy, pediatric maintenance dosing is 1.7 mg or 2.4 mg weekly; the 7.2 mg injection is adult-only. Mounjaro, Victoza, and Trulicity have a pediatric type 2 diabetes use starting at age 10. Zepbound, Ozempic, Foundayo, and Wegovy tablets do not have a pediatric indication.

This comes first for a reason. The exact drug, form, diagnosis, and age decide which FDA label and plan policy apply. If the request names the wrong product, it can be sent into the wrong review lane before anyone reaches the strongest part of your teen’s chart.

GLP-1 and incretin medicines for teens — labels checked September 24, 2026

The current labels are the starting point, not a promise of payment. See the Wegovy prescribing information, Saxenda prescribing information, Mounjaro prescribing information, Victoza prescribing information, Trulicity prescribing information, Zepbound prescribing information, and Ozempic prescribing information.

Four things parents get tripped up on:

• Zepbound and Mounjaro are not the same coverage request. They contain tirzepatide, but the current pediatric indication is for Mounjaro in type 2 diabetes. That does not create a pediatric Zepbound weight-management indication.
• It is a percentile, not an adult BMI cutoff. For children and teens, clinicians use BMI-for-age percentiles on a growth chart. A plan may ask for the percentile, the measurement date, and the underlying height and weight.
• The exact form and strength matter. The standard Wegovy injection pathway has the pediatric indication. Wegovy tablets and the 7.2 mg injection do not.
• Ozempic is not a stand-in for Wegovy. Both contain semaglutide, but they have different labels and coverage policies. For adolescent weight management, the request should name the pediatric Wegovy injection pathway when that is what the clinician prescribed.

Is CHIP the same as Medicaid for GLP-1 coverage?

No. States can cover children through Medicaid-expansion CHIP, a separate CHIP program, or both. A child in Medicaid-expansion CHIP receives the Medicaid benefit package, including EPSDT. A child in separate CHIP receives the state’s separate benefit package, and EPSDT applies only if the state elected it for that population.

KFF’s children-specific state indicator reflects policies in place as of January 2026. It marks 22 jurisdictions as N/A (M-CHIP) because children’s CHIP runs through Medicaid. It reports full EPSDT in separate CHIP in 14 states. Florida did not report a status. Those are benefit-framework findings, not GLP-1 formulary decisions.

The 2-minute call that settles the starting point

You do not need to guess. Call the member-services number on your teen’s card and say:

“I am calling about prescription coverage for my child, age [age]. Is my child enrolled through Medicaid-expansion CHIP or separate CHIP? Does EPSDT apply to my child’s exact eligibility group? Is [exact medicine and form] covered for [exact diagnosis]? Is prior authorization required? Please tell me where the current formulary, clinical criteria, PA form, and appeal instructions are posted.”

Before you hang up, write down:

• the date and time
• the representative’s name or ID
• the call-reference number
• the exact answer
• the title or URL of every document the representative used

Those notes do not replace the written policy. They give you a clean record if the next answer conflicts with the first one.

What is EPSDT, and does it make CHIP cover GLP-1s?

EPSDT stands for Early and Periodic Screening, Diagnostic, and Treatment. It is the Medicaid benefit for people under 21. It requires states to arrange and cover Medicaid services that are medically necessary to correct or ameliorate a condition. It does not automatically approve a drug, skip prior authorization, or force payment for a particular brand.

Think of EPSDT as a child-specific coverage rule, not a magic word. It tells Medicaid to look at what the individual child needs under the Medicaid benefit. The state still defines medical necessity within federal limits, and the pharmacy benefit can still use lawful utilization controls.

Federal law separately allows Medicaid programs to exclude or restrict drugs used for anorexia, weight loss, or weight gain. That is why the safest, most accurate request is not “EPSDT means you must pay for this brand.” It is:

“Please issue a written, child-specific decision that explains how EPSDT, the Medicaid pharmacy benefit, the exact FDA-labeled pediatric use, and the plan’s medical-necessity criteria were applied to this request.”

The adult rule is not the whole answer. If member services says, “We do not cover weight-loss drugs,” ask whether that answer came from an adult policy or the child’s actual benefit. Then ask for the written rule and a formal decision on the exact pediatric request.

What EPSDT does not change:

• the clinician still has to document the diagnosis and medical need
• the exact drug and formulation still matter
• the plan can request records and use PA
• separate CHIP does not get EPSDT automatically
• a pharmacy rejection is not always the formal appealable decision

CMS explains the benefit in its EPSDT overview. The current separate-CHIP election list appears in CMS’s August 2026 toolkit.

Does CHIP cover GLP-1 for teens in my state?

The state table gives you the benefit starting point, not a drug-coverage verdict. It follows KFF’s children-specific EPSDT in Separate CHIP indicator for policies in place as of January 2026. You still need the exact plan formulary, PA policy, and written decision on your teen’s request.

How to read the table:

• N/A — children’s CHIP runs through Medicaid: KFF reports that the state does not use a separate CHIP program for uninsured children. EPSDT applies through Medicaid-expansion CHIP.
• Yes — full EPSDT reported in separate CHIP: KFF reports that the separate CHIP program provides the full Medicaid EPSDT benefit.
• No full EPSDT benefit reported for separate CHIP: do not assume the full Medicaid child benefit applies to a teen in separate CHIP. If the teen is in Medicaid-expansion CHIP, EPSDT still applies.
• Not reported: KFF did not receive a state response. Confirm the program type and EPSDT status directly with the plan and state.

KFF’s national row reports 22 jurisdictions marked N/A (M-CHIP) and 14 states marked Yes. Florida is marked NR. A state-table result does not tell you whether Wegovy, Saxenda, or another medicine is on the current formulary.

The RX Index CHIP EPSDT starting-point table — source status as of January 2026; checked September 24, 2026

What this table does not say: it does not say Wegovy or Saxenda is on the plan’s formulary. It does not say a PA will be approved. It does not replace a current member handbook, drug list, or formal notice. “No full EPSDT benefit reported” is not the same as “the drug is excluded.”

The reader-facing status comes from KFF’s EPSDT in Separate CHIP state indicator, which reflects policies in place as of January 2026. CMS’s EPSDT overview and CHIP program information explain the federal framework. Oregon’s approved state-plan amendment separately confirms its transition to Medicaid-expansion CHIP effective January 1, 2024.

What we found when we read Texas’s standard Wegovy checklist Texas’s published Medicaid Wegovy criteria, revised May 8, 2026, ask whether the patient is 18 or older. A “no” ends the standard checklist. The published pathway then focuses on adult cardiovascular-disease or MASH indications, and an approval under that standard form lasts 365 days. What that proves: the standard published Texas checklist is not a ready-made pediatric obesity pathway. What it does not prove: it does not prove that every Texas Medicaid or CHIP request for a teen must end there. A Medicaid-enrolled teen’s clinician can ask for a written child-specific decision and explain why the standard adult checklist does not answer the pediatric request. A teen in separate Texas CHIP needs the current CHIP formulary, exception rule, and appeal process from the plan. Read the Texas Wegovy clinical criteria. Do not assume the adult form is your teen’s final answer.

Found your state? Good. Now do the plan-specific part: identify the exact plan, the exact medicine and form, the current formulary entry, the PA form, and the person or portal that receives it.

See my state’s next steps →

Pick your state, the medicine, the diagnosis, and where you are in the process. The under-18 result gives you the exact questions to ask and the records to bring. No sign-up is required to see the checklist.

Does CHIP cover Wegovy for teens?

CHIP can cover the standard Wegovy injection pathway for a teen age 12 or older with obesity, but it is not automatic. Pediatric maintenance dosing is 1.7 mg or 2.4 mg weekly. Wegovy tablets and the 7.2 mg injection do not have a pediatric indication. The plan still checks its benefit, formulary, PA criteria, and the facts in the individual request.

Wegovy is the medicine most parents mean when they ask this question. A strong request often includes:

• the teen’s age
• the diagnosis of obesity
• current height, weight, and BMI-for-age percentile with the measurement date
• related health conditions, when relevant
• the exact prescribed product and strength: the pediatric Wegovy injection pathway, not Wegovy tablets or the 7.2 mg adult dose
• the clinician’s reason for choosing it
• the support already in place for nutrition, activity, sleep, and follow-up
• the plan’s own completed PA form
• a monitoring and renewal plan

Only your plan’s written criteria count. Do not copy a commercial insurer’s rule, an adult Medicaid policy, or a requirement from another state and assume it applies. Ask the plan to send the current pediatric policy or give you the exact document title and revision date.

Plan for renewal on day one. An approval normally has an end date. Save the approval letter, put the date on your calendar, and ask what the plan will need for continuation. Updated measurements, visit notes, treatment response, side effects, and proof of ongoing clinical follow-up may matter.

Our Wegovy for teens insurance coverage guide covers the broader Wegovy PA process for private and commercial insurance. This page stays focused on CHIP, Medicaid-expansion CHIP, EPSDT, and state review paths so the two pages do not compete for the same job.

Does type 2 diabetes change what CHIP covers?

Yes. Type 2 diabetes and obesity are different diagnosis and coverage lanes. Mounjaro, Victoza, and Trulicity have FDA-approved type 2 diabetes uses starting at age 10. That does not make them approved pediatric weight-management medicines, and it does not make Zepbound or Ozempic interchangeable with them.

The line to remember: a plan’s coverage of Mounjaro for a teen’s type 2 diabetes does not prove it covers tirzepatide for adolescent weight management.

For Medicaid, covered-outpatient-drug rules, manufacturer participation, the state formulary, and utilization controls all matter. Prior authorization or step therapy may still apply. Separate CHIP can use its own drug benefit. Ask about the exact medicine and the true diagnosis instead of asking only, “Do you cover GLP-1s?”

We are not suggesting anyone change a diagnosis to get coverage. The clinician documents what is true, and the true diagnosis decides the review lane.

What does CHIP need from my teen’s doctor?

Many CHIP and Medicaid plans require prior authorization. A strong request identifies the teen, diagnosis, age, measurements, exact medicine and form, medical reason, relevant history, and follow-up plan. The plan’s current written criteria must control the final packet.

The doctor-ready checklist

• ☐ Age and diagnosis. State the exact diagnosis and any related conditions that matter to the request.
• ☐ Growth chart. Include current height, weight, BMI-for-age percentile, and measurement date.
• ☐ Relevant history. Include prior care, nutrition support, activity plans, counseling, or other treatment the plan actually asks about. Add dates and results.
• ☐ Exact medicine, form, and strength. For Wegovy, identify the pediatric injection pathway—not the tablets or the 7.2 mg adult dose. For every request, do not write only “semaglutide” or “GLP-1.”
• ☐ Why this medicine, why now. Connect the FDA-labeled pediatric use, the teen’s condition, prior care, and the clinician’s judgment.
• ☐ Safety screening. Address the contraindications and warnings that apply to the prescribed medicine.
• ☐ Follow-up plan. Explain how the clinician will monitor growth, nutrition, eating patterns, side effects, and treatment response.
• ☐ For Medicaid or Medicaid-expansion CHIP: clearly request a child-specific medical-necessity decision under EPSDT.
• ☐ The plan’s current form. Use the correct form and confirm every required field and attachment.
• ☐ A written decision. Ask the plan to send the reason, policy, deadline, and appeal route if it does not approve the request.

The American Academy of Pediatrics’ 2023 obesity guideline says clinicians should offer adolescents age 12 and older with obesity weight-management pharmacotherapy, according to the medicine’s indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment. That supports clinical context. It does not replace the plan’s policy or decide whether a particular teen should use a medicine.

What to write for an EPSDT request

EPSDT uses the phrase “correct or ameliorate.” In plain words, that means care needed to correct, improve, maintain, or reduce the effects of a condition. The clinician’s letter should connect the facts instead of dropping the acronym into one sentence.

• The condition: the diagnosis, measurements, and related health effects.
• What has already happened: prior care and what the records show.
• Why the requested treatment is medically necessary: how it is expected to correct or ameliorate the condition for this teen.
• Why this exact product and form: the pediatric indication and the clinical reason for the choice.
• How the teen will be followed: visits, measurements, safety checks, and renewal plan.
• What decision is requested: a written child-specific determination under EPSDT and the Medicaid pharmacy benefit.

How long does prior authorization take?

• Medicaid, including Medicaid-expansion CHIP: federal Medicaid drug law requires a response to a drug PA request within 24 hours. That is a response rule, not a promise of approval. The same federal provision requires a process for a 72-hour emergency supply when the PA request has not yet been resolved.
• Separate CHIP: use the plan’s stated turnaround time. Ask whether it measures calendar days or business days and what qualifies for expedited review.
• Any plan: if the request appears stuck, ask whether the plan received the form, whether it is complete, which decision clock applies, and when the written response is due.

Track five things from day one:

1. The date and method the request was sent
2. The submission or reference number
3. Every missing item the plan requested
4. The date and wording of the decision
5. The approval end date or appeal deadline

Do not walk into the appointment empty-handed. Bring one page that tells the office which plan, medicine, diagnosis, policy, and form apply. Offices juggle hundreds of requests. A clean packet makes it easier for the clinician to answer the right question the first time.

Build the doctor-ready checklist →

Choose your state, CHIP type, medicine, diagnosis, and current stage. The tool turns those answers into a printable checklist without asking for personal identifiers.

Why did CHIP deny my teen’s GLP-1?

The word “denied” can hide very different problems. A pharmacy rejection may mean PA has not been submitted. A formal adverse benefit decision should explain the plan’s reason and appeal rights. The correct next step depends on whether the problem is missing information, the wrong product, a formulary rule, a clinical decision, or a benefit exclusion.

Five problems cause many failed requests:

• missing or incomplete paperwork
• the wrong drug, diagnosis, or formulation
• a formulary or step-therapy rule
• a “not medically necessary” decision
• a benefit or category exclusion

We built this decoder because sending more records will not fix every problem, and a formal appeal is slower than a corrected resubmission when all that is missing is one chart note.

The denial decoder

A paperwork “no” can often be fixed faster than a full appeal. A true exclusion or clinical denial may need formal review. Either way, the next step is the same: get the exact reason, policy, and deadline in writing.

How do I appeal a CHIP GLP-1 denial?

Start with the formal written notice. It tells you what was denied, why, when the decision takes effect, how to appeal, and which deadline applies. In Medicaid and separate-CHIP managed care, the federal plan-appeal filing window is generally 60 calendar days from the notice. The actual notice controls your case.

If your teen’s card names a managed-care health plan, use that plan’s appeal process first unless the notice says otherwise.

If the plan is stopping medicine your teen already receives

Do not assume coverage continues automatically. Medicaid managed-care continuation requires several conditions, including:

• the appeal is filed on time
• the appeal challenges a termination, suspension, or reduction of a previously authorized service
• the original authorization period has not expired
• the teen was receiving the service under that authorization
• you ask for continued benefits

For this purpose, “timely” generally means within 10 calendar days after the plan sends the notice or before the intended effective date, whichever is later. Read the notice and act immediately. Separate CHIP continuation rights can differ, so ask the plan what protects ongoing treatment during appeal.

No managed-care company on the card?

Your teen may receive some or all coverage directly from the state. Follow the state notice. Federal Medicaid hearing rules let a state set a filing deadline no longer than 90 days from the notice, but your state may use a shorter period.

Can the clinician appeal for us?

A clinician or another representative may be able to help or act for the enrollee with written authorization, subject to the plan and state rules. Ask for the authorized-representative form. Do not assume the clinician’s office filed the appeal until you have a confirmation number.

Build a strong appeal packet

• ☐ The complete denial or adverse-benefit notice
• ☐ A one-page cover letter naming the decision and the requested remedy
• ☐ The policy or criterion the plan used
• ☐ The original PA request
• ☐ Corrected or missing records
• ☐ The clinician’s medical-necessity letter
• ☐ Growth-chart and current measurement records when relevant
• ☐ The EPSDT request and child-specific explanation when it applies
• ☐ Your call and submission log
• ☐ Proof of delivery
• ☐ The filing deadline in large type on the first page of your own copy

Need it faster? Ask for expedited review only when the standard timeframe could seriously jeopardize the teen’s life, physical or mental health, or ability to attain, maintain, or regain maximum function. The clinician should explain the urgency in writing.

This is where most families give up. Do not. You now know which deadline to find, which review level comes next, and what belongs in the packet. That is enough to turn a vague “no” into a specific task.

Build my appeal-packet checklist →

Enter the denial reason, program type, and notice stage. The under-18 result gives you a packet checklist and keeps the deadline in view. It does not promise an outcome or replace legal advice.

How much will a GLP-1 cost through CHIP?

If the plan approves the medicine, the exact copay depends on the program, income rules, and plan. Do not promise $0. Medicaid and CHIP use federal cost-sharing limits, but the amount can differ by state and eligibility group.

What the current Wegovy cash price adds up to: using the prices listed on September 24, 2026, two starter fills at $199 plus ten fills at $349 equals $3,888 for 12 fills. Twelve fills at $349 equals $4,188. The $199 starter offer is currently listed through December 31, 2026, so treat that math as a current-price illustration, not a locked annual contract.

That math is the whole reason this page exists. One accurate call, one complete packet, and one timely appeal can be worth thousands of dollars. It can also save a family from paying cash before learning that a fixable PA problem caused the rejection.

Check the current NovoCare Wegovy savings and self-pay terms before relying on any price.

Is a GLP-1 safe for my teen?

Safety depends on the medicine, the teen’s health, and the clinician’s follow-up. The American Academy of Pediatrics recommends that clinicians offer adolescents age 12 and older with obesity weight-management pharmacotherapy according to each medicine’s indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment. That is a recommendation to consider treatment, not a recommendation that every teen use it.

In the STEP TEENS trial, adolescents assigned to semaglutide had a mean BMI change of −16.1% at 68 weeks, compared with +0.6% with placebo. The study also reported more gastrointestinal adverse events with semaglutide. A trial average does not predict one teen’s result, and coverage does not prove the medicine is right for that teen.

What the Wegovy label asks families to take seriously

• Common adverse reactions in adolescents include nausea, diarrhea, vomiting, constipation, and abdominal pain.
• The boxed warning concerns thyroid C-cell tumors seen in rodents. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Other label warnings include acute pancreatitis, gallbladder disease, hypoglycemia with insulin or an insulin secretagogue, acute kidney injury related to dehydration, severe gastrointestinal adverse reactions, hypersensitivity, and increased heart rate.
• Follow-up matters. A pediatric clinician can track growth, nutrition, eating patterns, symptoms, side effects, and whether the treatment should continue.

Long-term pediatric evidence is still smaller than adult evidence. That is one more reason the right prescriber is a clinician who treats minors and will see the teen again. Your teen’s clinician makes the medical decision. This page helps with the coverage decision.

Read the AAP clinical practice guideline and the STEP TEENS study record for the underlying evidence.

Can my teen use an online GLP-1 program instead?

Do not use an adult direct-to-consumer GLP-1 program as the default path for a minor. A teen needs a clinician and service that are legally able and clinically set up to treat minors, obtain the required consent, assess the teen, coordinate follow-up, and handle the insurance paperwork.

If you have seen an ad for low-cost “semaglutide” or “tirzepatide,” it is reasonable to ask what it is. Here is the part that matters:

• Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before they are marketed.
• FDA has received reports involving dosing errors with compounded semaglutide. Product concentration, measuring units, and syringes can create confusion.
• A compounded product is not the same coverage request as Wegovy, Saxenda, Mounjaro, or another FDA-approved product. Do not use it to blur an adult cash-pay offer with a pediatric FDA-labeled treatment path.
• Cash paid outside CHIP does not fix the denial. It does not create plan coverage, satisfy PA, or preserve appeal rights by itself.

Where to go instead:

• Your teen’s pediatrician: ask whether the teen should be evaluated for an FDA-approved pediatric option.
• A pediatric weight-management program: many children’s hospitals use a team approach and can help with PA.
• A pediatric endocrinologist or adolescent-medicine clinician: especially when diabetes, growth, endocrine issues, or complex medical history are involved.
• The plan’s member line: ask which pediatric weight-management or endocrinology clinics are in network.

FDA explains the difference in its compounded-drug risk guide.

Will the federal BALANCE Model help my teen?

Not for the model’s Medicaid weight-management population. CMS’s BALANCE state application defines that population as Medicaid beneficiaries age 18 and older. A teen’s coverage question still turns on the existing CHIP or Medicaid benefit, the exact drug policy, EPSDT when it applies, and the individual PA.

As of the CMS page’s August 14, 2026 update, the model was still listed as Announced and the participant field showed N/A. Even when states begin participating, the model’s adult weight-management pathway does not replace a teen’s current coverage and appeal rights.

Read the CMS BALANCE Model page for updates. Do not wait for BALANCE before filing a current teen PA or appeal.

What happens when my teen turns 19?

Children’s CHIP eligibility generally ends at age 19. If the young adult qualifies for Medicaid, EPSDT continues through age 20 because the federal benefit covers people under 21. If the next coverage is a job-based plan, Marketplace plan, student plan, or adult Medicaid group, the new plan’s adult formulary and PA rules apply.

If your teen is close to 19:

• Ask what coverage comes next now. Do not wait for the last fill.
• Save the full record. Keep the approval, denial, appeal, measurements, visit notes, and current medication list.
• Check the new plan before the old approval ends. An approval normally does not transfer between plans.
• Ask about transition fills or continuity rules. Get any answer in writing.
• Start the new PA early. The new plan may use different criteria even when the medicine stays the same.

If you are a parent thinking about treatment for yourself: your coverage path is separate from your teen’s.

• On Medicaid yourself? Start with Medicaid GLP-1 coverage by state.
• Have private insurance or plan to self-pay? Use Find My GLP-1 Path to compare adult treatment paths. The adult branch is separate from the pediatric CHIP checklist.

How we checked this page

We built the reader-facing state table from KFF’s EPSDT in Separate CHIP indicator, which reports state policies in place as of January 2026. We used current CMS sources to explain the federal Medicaid-expansion CHIP, separate CHIP, and EPSDT framework, and Oregon’s approved amendment as an additional state-program check. Medicine ages and uses come from current prescribing information. Appeal timelines come from federal regulations. Prices come from the current manufacturer page.

The RX Index is independent guidance for choosing your GLP-1 path. We score providers and treatment paths on what actually matters — clinical legitimacy, care quality, transparency, access, and cost — then help readers decide where to start. We are not a doctor, insurer, pharmacy, state agency, or law firm.

How we classified each state

• N/A (M-CHIP): KFF reports that the state does not administer a separate CHIP program for uninsured children. Children’s CHIP runs through Medicaid, so EPSDT applies.
• Yes: KFF reports that the separate CHIP program provides the full Medicaid EPSDT benefit.
• No full EPSDT benefit reported: KFF’s state row is not marked Yes or N/A. A teen in Medicaid-expansion CHIP still receives EPSDT; a teen in separate CHIP needs the separate benefit, formulary, and exception rules.
• Not reported: KFF did not receive a response from the state for that indicator. The plan and state must confirm the current status.

The limits, stated plainly

• Program structures, plan contracts, formularies, and PA policies can change.
• The reader-facing KFF state table reflects policies in place as of January 2026; a state or plan may change after that date.
• A state-level classification cannot answer an individual plan’s drug coverage.
• A formulary entry cannot predict individual medical-necessity approval.
• A phone answer is not stronger than the current written policy or formal notice.
• We cannot see your teen’s card, chart, plan documents, or denial notice.

What we verified on September 24, 2026

• federal CHIP and EPSDT rules
• KFF’s dated children-specific EPSDT status for all 50 states and the District of Columbia
• Oregon’s approved transition to Medicaid-expansion CHIP
• the current federal Medicaid-expansion CHIP, separate CHIP, and EPSDT framework
• federal Medicaid and CHIP managed-care appeal rules
• the Medicaid drug PA response rule
• current pediatric label status for the medicines named on this page
• Texas Medicaid’s standard Wegovy checklist dated May 8, 2026
• current NovoCare Wegovy self-pay terms
• the BALANCE Model’s adult Medicaid weight-management age rule

What we did not verify

• every managed-care plan’s current formulary
• every state’s drug-exception form
• every plan’s renewal rule
• your teen’s medical eligibility
• whether any particular request or appeal will be approved

Why there are no parent testimonials here

One family’s approval does not predict another family’s result. A treatment story also cannot prove safety or effectiveness. On a minors page, dated official documents, current labels, a clear method, and an honest statement of limits are better evidence than an anonymous success story.

Update schedule

Found something outdated? Tell us. We correct material errors and update the verification date only after rechecking the underlying sources.

Frequently asked questions

Does CHIP cover Wegovy for teens?

It can. The standard Wegovy injection pathway has an FDA-approved weight-management use for pediatric patients age 12 and older with obesity. Pediatric maintenance dosing is 1.7 mg or 2.4 mg weekly. CHIP payment still depends on the teen’s program, plan formulary, PA criteria, and individual records. Wegovy tablets and the 7.2 mg injection do not have a pediatric indication.

Does CHIP cover Ozempic for teens?

Ozempic does not have a pediatric indication under its current prescribing information. For adolescent weight management, the FDA-labeled semaglutide path is the standard Wegovy injection pathway—not Wegovy tablets or the 7.2 mg adult dose. For type 2 diabetes, the clinician and plan should use the exact pediatric diabetes policy instead of treating “Ozempic” as a name for every semaglutide product.

Does CHIP cover Zepbound for teens?

Zepbound does not have a pediatric indication under its current label. Mounjaro’s pediatric type 2 diabetes indication does not carry over to Zepbound for adolescent weight management. Ask the clinician and plan about an FDA-labeled pediatric option.

Is CHIP the same as Medicaid?

Not always. A state can use Medicaid-expansion CHIP, separate CHIP, or both. Call the number on the card and ask, “Is my child enrolled through Medicaid-expansion CHIP or separate CHIP, and does EPSDT apply to this exact eligibility group?”

Does EPSDT guarantee my teen gets a GLP-1?

No. EPSDT requires a child-specific application of Medicaid’s medical-necessity rules for covered services. It does not guarantee a particular drug, skip PA, or turn an adult-only product into a pediatric one.

Can a 12-year-old get Wegovy through CHIP?

The standard Wegovy injection pathway has a pediatric weight-management indication beginning at age 12 for patients with obesity. Pediatric maintenance dosing is 1.7 mg or 2.4 mg weekly; Wegovy tablets and the 7.2 mg injection do not have a pediatric indication. CHIP still has to cover the product and approve the individual request. Age alone is not an approval.

How long does CHIP take to approve a GLP-1?

It varies. Medicaid drug PA systems must respond within 24 hours, but that is not an approval guarantee. Separate CHIP uses its plan timeframe. Ask when the clock starts, whether the request is complete, and when the written answer is due.

Does CHIP cover GLP-1 medicines for teens with type 2 diabetes?

It may. Mounjaro, Victoza, and Trulicity have type 2 diabetes indications starting at age 10. The plan can still use its pediatric diabetes formulary, PA, step-therapy, and medical-necessity rules.

Can we use NovoCare’s Wegovy self-pay price with CHIP?

Current NovoCare terms say a government-insured patient may use the self-pay offer by filling outside insurance. The payment is not a CHIP claim and does not count toward plan cost sharing, a deductible, or an out-of-pocket limit. Recheck the terms before paying because prices and eligibility can change.

How long do I have to appeal a CHIP denial?

For Medicaid and separate-CHIP managed care, the federal plan-appeal window is generally 60 calendar days from the notice. If the plan upholds the denial, the state must allow between 90 and 120 calendar days from the resolution notice to request the Medicaid state fair hearing or separate CHIP state external review. Always follow the date and instructions on the actual notice.

Can my teen’s clinician appeal for us?

Often, with the required written authorization and subject to plan and state rules. Ask for the authorized-representative form and keep the submission confirmation. Do not assume the office filed until you have proof.

Is compounded semaglutide okay for a teen?

Compounded semaglutide is not FDA-approved, and FDA does not review compounded products for safety, effectiveness, or quality before marketing. This page does not present compounded medication as a substitute for an FDA-approved pediatric product. Talk with a clinician who treats minors.

What happens to coverage when my teen turns 19?

Children’s CHIP eligibility generally ends at age 19. If the young adult qualifies for Medicaid, EPSDT continues through age 20. Otherwise, the next adult plan’s formulary and PA rules apply, so start the transition before the last covered fill.

Once CHIP approves the medicine, does coverage last?

Not forever. Approvals usually have an end date and renewal criteria. Save the letter, confirm the renewal rule, and begin before the approval expires. Do not assume the first approval automatically renews.

What does “Yes” in the state table prove?

It means KFF reports that the state’s separate CHIP program provides the full Medicaid EPSDT benefit. It does not prove that a medicine is on the formulary or that an individual PA will be approved.

Sources

Federal CHIP, Medicaid, and appeal rules

• CMS / Medicaid.gov: Children’s Health Insurance Program
• CMS / Medicaid.gov: Early and Periodic Screening, Diagnostic, and Treatment
• KFF: EPSDT in Separate CHIP state indicator (policies in place as of January 2026)
• CMS: August 2026 toolkit with additional separate-CHIP EPSDT background
• KFF: Medicaid and CHIP eligibility, enrollment, and renewal policies (published April 30, 2026; policies as of January 2026)
• Oregon Health Authority: State Plan Amendment 24-0006
• CMS / Medicaid.gov: CHIP cost sharing
• CMS / Medicaid.gov: Medicaid cost sharing
• eCFR: 42 CFR 438.402 — managed-care appeal process
• eCFR: 42 CFR 438.408 — appeal resolution timing
• eCFR: 42 CFR 438.420 — continuation of benefits
• eCFR: 42 CFR 457.1260 — separate CHIP appeals and state external review
• Social Security Act: Section 1927 — Medicaid outpatient drugs and PA response

Prescribing information and medical evidence

• FDA: Wegovy prescribing information
• Novo Nordisk: Saxenda prescribing information
• Eli Lilly: Mounjaro prescribing information
• Novo Nordisk: Victoza prescribing information
• Eli Lilly: Trulicity prescribing information
• Eli Lilly: Zepbound prescribing information
• Novo Nordisk: Ozempic prescribing information
• FDA: Foundayo prescribing information
• American Academy of Pediatrics: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
• Weghuber et al.: Once-Weekly Semaglutide in Adolescents with Obesity
• FDA: Understanding the risks of compounded drugs

Current policy and price examples

• Texas Prior Authorization Program: Wegovy clinical criteria (May 8, 2026)
• NovoCare: Wegovy savings and self-pay terms
• CMS: BALANCE Model
• CMS: BALANCE State Medicaid Request for Applications

This guide is for education, not medical or legal advice. Coverage rules change. Confirm the current details with your teen’s plan and clinician before making a decision. Last verified September 24, 2026 by The RX Index.

Related guides:

• Wegovy for teens insurance coverage
• Medicaid GLP-1 coverage by state
• GLP-1 appeal levels explained
• GLP-1 BMI eligibility chart

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Start Find My GLP-1 Path →

If the patient is under 18, the tool opens a pediatric CHIP coverage checklist. It never matches a teen to an adult telehealth program or compounded medication.